Literature DB >> 1858743

Acinar cell carcinoma of the pancreas: a rare cause of left-sided portal hypertension.

S M Sheen-Chen1, H L Eng, Y L Wan, F F Chou.   

Abstract

Isolated splenic vein obstruction with left-sided portal hypertension is a rare clinical condition. Owing to the close relationship of the splenic vein and the pancreas, this rare phenomenon is usually secondary to pancreatic inflammation or neoplasm. Acinar cell carcinoma has long been recognized as a distinctive, rare type of pancreatic carcinoma. A case of isolated splenic vein obstruction with left-sided portal hypertension secondary to acinar cell carcinoma of the pancreas, which we are reporting here, is thought to the first documented in the literature.

Entities:  

Mesh:

Year:  1991        PMID: 1858743

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

1.  Pattern of venous collateral development after splenic vein occlusion in an extended Whipple procedure : comparison with collateral vein pattern in cases of sinistral portal hypertension.

Authors:  Steven M Strasberg; Sanjeev Bhalla; Luis A Sanchez; David C Linehan
Journal:  J Gastrointest Surg       Date:  2011-09-13       Impact factor: 3.452

2.  Preoperative splenic artery embolism followed by splenectomy is safe and effective in patients with sinistral portal hypertension.

Authors:  Zihe Wang; Mao Li; Xing Huang; Junjie Xiong; Bole Tian
Journal:  Langenbecks Arch Surg       Date:  2021-09-19       Impact factor: 2.895

Review 3.  Sinistral portal hypertension.

Authors:  Richard J Thompson; Mark A Taylor; Lloyd D McKie; Thomas Diamond
Journal:  Ulster Med J       Date:  2006-09

Review 4.  Case report and systematic literature review of a novel etiology of sinistral portal hypertension presenting with UGI bleeding: Left gastric artery pseudoaneurysm compressing the splenic vein treated by embolization of the pseudoaneurysm.

Authors:  Seifeldin Hakim; Jared Bortman; Molly Orosey; Mitchell S Cappell
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.